Top Midday Gainers
1:32PM ET 5/10/2022 MT NewswiresBiohaven Pharmaceutical (BHVN) surged past 70% after Pfizer (PFE) agreed to acquire Biohaven's remaining shares that it didn't already own for $11.6...
Quotes Snapshot > FGEN
FibroGen Inc FGEN:NASDAQ
Last Price$8.41NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22
Today's Change-0.79(8.59%)
Bid (Size)$7.00 (1)
Ask (Size)$15.80 (20)
Day Low / High$8.22 - 9.11
Volume853.6 K
Read more news Recent News
FibroGen Q1 Loss Narrows, Revenue Rises
4:17PM ET 5/09/2022 MT NewswiresFibroGen (FGEN) reported late Monday a Q1 loss of $0.68 per diluted share, compared with a loss of $0.78 a year earlier. Analysts polled by Capital IQ...
-- Earnings Flash (FGEN) FIBROGEN Reports Q1 Revenue $60.8M, vs. Street Est of $28.8M
4:14PM ET 5/09/2022 MT Newswires...
-- Earnings Flash (FGEN) FIBROGEN Reports Q1 Loss $-0.68, vs. Street Est of $-0.92
4:13PM ET 5/09/2022 MT Newswires...
View all Commentary and Analysis
FibroGen, Inc.'s (FGEN) CEO Enrique Conterno on Q1 2022 Results - Earnings Call Transcript
11:25PM ET 5/09/2022 Seeking AlphaFibroGen (FGEN) Investor Presentation - Slideshow
10:55AM ET 3/12/2022 Seeking AlphaArtelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy
9:18PM ET 3/08/2022 Seeking AlphaFibroGen, Inc. 2021 Q4 - Results - Earnings Call Presentation
4:13PM ET 3/04/2022 Seeking AlphaCompany Profile
Business DescriptionFibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA. View company web site for more details
| Address | 409 Illinois Street San Francisco, California 94158-2509 |
| Phone | +1.415.978.1200 |
| Number of Employees | 461 |
| Recent SEC Filing | 05/09/2022 10-Q |
| Chief Executive Officer & Director | Enrique A. Conterno |
| Chief Financial Officer & Senior Vice President | Juan Graham |
| Senior Vice President-Technical Development | Michael Martinelli |
| Senior VP-Clinical Development & Drug Safety | Elias Kouchakji |
Company Highlights
| Price Open | $8.93 |
| Previous Close | $8.41 |
| 52 Week Range | $7.81 - 30.12 |
| Market Capitalization | $784.6 M |
| Shares Outstanding | 93.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$3.04 |
| Beta vs. S&P 500 | N/A |
| Revenue | $213.0 M |
| Net Profit Margin | -109.22% |
| Return on Equity | -118.07% |
Analyst Ratings as of 03/01/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |